Which insulin and IU patient will get? Insulin and IU patient will get. I'll talk about in a second. We've initiated a IB trial here for nin tedanib. That'll be mainly in the U.S. to satisfy the FDA to go into phase III. We have INFLOW 2, which will be going out ex- U.S., and that will be the bridge to the phase III dosing. I'll start off with the newest acquisitions, and that's where we get a lot of our questions here. FUROSCIX, for you don't know, is an on-body infuser with furosemide. It's really meant to really handle the IV load that happens in the hospitals. There's over a $10 billion opportunity here when you think about the 6 million people in the U.S. and the 16 million in the G7 that have heart failure. There's about 2.1 million fluid edemic episodes here in the U.S., and about 80% of that cost is hospitalization. That hospitalization is mostly because patients cannot get IV Lasix at home. They go in the hospital for 5-7 days, and then oftentimes about 25% of the patients are readmitted 30 days later or within 30 days, and there's penalties at the hospitals in the U.S. CMS has been struggling for years to manage this cost and the readmissions and the penalties. There's a new opportunity next year coming out called AMC, which is really gonna be a penalty for the physician's personal financial interest, plus or minus, I think it's 15%-20% of their pay, just if they handle their heart failure patients properly and reduce readmissions. That's different than a hospital payment penalty. It's really going to the physicians now who provide the care. When you think about FUROSCIX net revenue, it was in launch mode. They launched with a small sales force, then moved up a little bit in 2024, and then late 2024 they expanded again to 80 reps. When you look at that trajectory and that growth, it did $19.3 million in Q3, and we're on track to have a decent Q4 when you think about up 93% year-over-year. When you look at doses dispensed, you can see a nice big jump here with the sales force expansion and continued execution and awareness, over 61,000 doses dispensed and 27,000 in Q3 alone. One of the questions we've been getting is, what is the nephrology? That was a new indication here in Q2, with this product. About 15% of the sales in Q3 were nephrology. That continues to increase as we go into Q4. That will be an important growth driver as we go forward. I think the team at scPharma has done a great job, and we really want to build on their momentum. That is one of the reasons we looked at this acquisition. Number one, we saw that they had a good community footprint in the sales force. Where we felt we could add some value is really the hospital segment, building out the key account managers. They have been working on getting national contracts, but there is a gap between the national contract and the pull through of the health system. When you think about who cares about the cost of readmissions and the cost of the hospitalization, it's really the CFOs, the quality departments, the people dealing with CMS and Medicare. That is not necessarily the cardiologist on the front lines treating the patient. There is a lot more work to do in a health system when you think about expanding the opportunity and getting on protocols and discharge protocols, things like beds to med and that part. The other part is an increased share of voice in the sales force. When we think about where the product will be next year, sc was targeting about, I'll call it 5,000- 7,000 cardiologists and nephrologists. We think next year we'll have a lot more share of voice on that. We've already expanded some of our sales forces to have this product available in January 26th. We also have the ready for the auto injector you see here, which really just continues to reduce the hassle factor, I'll say, with the on-body infuser, which you have to sit on for 5 hours. Not sit on it, but you put on the body for 5 hours, you activate it, and then you throw it away. You can imagine somebody has to get up and go to the bathroom. That's what this product does. Having an on-body infuser, trying to get up, run around, an auto injector will make your life a little bit easier. Hopefully the caretakers who sometimes often give care for these patients will make the administration a lot easier. As we looked at the market and the opportunity, another one, on our technology of FDKP, for those of you who don't know, I'll talk about in a second, but it really can give you an IV-like experience. If you want something that has a fast onset, very, very quick CMAX gets in the body. We really looked at the bumetanide product as an opportunity where we could load the target dose. Bumetanide has a really fast onset of action, and we think that our FDKP- delivered technology will really deliver an IV-like experience for bumetanide with good bioavailability. That, that's our key there. That product gives the patients the ability to maybe take it more often than once a day if they wanted to diuresis and dry out the patient more. We believe we'll have two angles here in the market. When you think about the diuresis market, there's really three products, and these two probably make up 90% of the market. We'll hopefully have options available over the coming years for both the on-body infuser, an auto injector, and an inhaled version, really addressing all different patient types and patient settings. I'll bridge over to Tyvaso DPI, which again, marketed by United Therapeutics. You can see they've continued to do an excellent job quarter over quarter, year-over-year. We have $59 million in Q3 related revenue, up 15% year-over-year. When you look at the growth drivers at United Therapeutics, it's really the launch of the 80 µg continuing to help that patient burden in terms of higher doses. When you think about the IPF data that came out with TETON 2 here recently, bridging study, we expect to continue to work on and see what happens there. We also expanded our collaboration in August with a second investigational molecule. I'm gonna bridge over to nintedanib DPI. This is something we've been working on for over 5 years. Many people ask us, you know, where do we see this opportunity? It's really how our Technosphere technology is differentiated. We know from a dry powder inhalation, you really get deep lung delivery. You may have heard recently, we work on a nebulized formulation for clofazimine in 101, and that had some weird results last week. We're still digging in to figure out what happened there. We think that's, when you think about the dry powder, we know that powder technology way better than we do nebulizers. We feel the consistency of a deep lung penetration for IPF is important, and our inhaler platform has obviously been used. We've formulated over 45 molecules, and you get extensive distribution throughout the lungs. That, you know, an IPF patient gets oxygen, they breathe wherever the air is flying. We expect the drug to get deposited. That's really what we're looking at for Technosphere and being differentiated for IPF. We're doing a phase I trial mainly for the FDA so we don't have any headaches as we go into phase III. In the U.S., they wanted you to do a phase II on top of background therapy, placebo- controlled for 25+ weeks. I just don't think that's a trial that's gonna get through IRBs in the U.S. We decided to go ex- U.S. for our phase II, but get the phase I B study done in IPF patients. We have the whole package as we come back to them in 2027. You look at up to seven U.S. sites, about 24 patients between the two arms here. Really think about it as a 6 mg exposure a day and 8 mg exposure a day. There will be 2 mg cartridges TID and/or 4 mg twice a day. That will be enrolling here shortly, hopefully by the end of the year, if not early January, we should see the first patient dosed. The first dose will be in the office, so we'll know pretty quickly how that tolerability's going. The phase II study for inflow two is also kicking off, and that'll be, hopefully in Europe, Asia, and Latin America. Here you're looking at a 2:2 to 1:1 randomization, so call it 70 active on each dose and then 35 in each placebo arm. This is what the FDA was asking for. We know ex-U.S., you can dose for about 12 weeks on a placebo without any IRB concerns 'cause it takes about 12 weeks to get a patient, even if they want active treatment. There is a period of time that it takes to get that approved and worked up. We believe patients here can start and then roll over if they wanna go into the extension phase for 6 months. Everyone's asking, is 12 weeks enough? I think when you look at the impact that you're starting to see in FDC, 12 weeks is really when you start to see that differentiation. If we see absolutely nothing, we're not powering it for efficacy, but we hope to see when, with the combined arms, you'll see a differentiation over placebo. Again, there'll be some imputed data for patients going on beyond 12 weeks based on those trends. It's a 220, 210 patient study. We will start to see, you know, some patients at 6 months, some patients at 9 months. We expect to kind of find that to really narrow that target population for phase III. We did modify with TETON 2 data coming out. We think there's a world where, Tyvaso 4x a day and this product four times a day will be used in conjunction. We modified that from three times a day to four times a day, that you may have seen previously, when we presented in September. For those who know AFREZZA, this has been a long journey for the company. It's been FDA- approved for over 10 years. The reason that's important is, diabetes endocrinologists are often very conservative. When you think about GLPs, it's almost a $100 billion category. They've been around 20 years. They weren't new. The same thing with metformin, it's been around a long time. Now we think of it from causing cancer to preventing cancer. With AFREZZA, you know, the long-term tested time has stood there in safety. That was really the major hangup on AFREZZA in terms of why it didn't take off. There's some other issues around dosing and packaging. We've addressed all those. We've had over 75 trials backing the safety and efficacy of this product. We'll have some new data coming out next year as well. When you really think about indicated for type 1, type 2, large market globally, over half a billion people, taken at the start of a meal, you're not timing things and then really comparable to AID systems. That's a study that just came out earlier this year where everyone tells us, "Hey, we really like pumps," and it's about 50% of the penetration in type 1. We went head to head against what is perceived the best standard of care. No doctor expected AFREZZA plus a basal to be as good. For us, that was important, not necessarily for the adult community, but as we go into kids, we know that the pediatric market, the competition directly or indirectly will be doctors who won't use insulin pumps. That bridges me here. When you think about the pediatric market, and we're updating this for next year in terms of research, we asked, what% of your patients will try AFREZZA? You can see switching from MDI, you get about 28%, switching from AID systems, 14%. This is prior to the data we just generated that you saw this year. The reason we bring this up is this is really the inflection when we think about where AFREZZA's been. You know, if you look at CGM and Dexcom started in children, Omnipod started in kids, and then these innovations went to adults. They didn't rarely go to type 2 to then drive a, a differentiation when you think about insulin and insulin-dependent diabetes. Every 10% market share in kids is roughly $150 million in net revenue. Plus you take the $70 million-$75 million AFREZZA we'll do this year, you get to it over $200+ million brand in the near term growing. You can see the endocrinologists and caregivers and how they feel about this. Generally, if you do market research, you would discount this data by 50%. That's where we get to roughly a 10% share is our minimal assumption for success. When we presented the data earlier this year at ATTD, the thing that came out was some clinicians who said, you know, really where this belongs is the very first insulin. While we agree as a company, we were surprised to hear that because so many times these institutions are set up on injectable insulin. They have the parents come back multiple times, and they kind of have this entire training curriculum to get 'em to an insulin pump. We wind up fighting for that patient after they've already started insulin, after they've already started on a pump. You are trying to find that intervention point along the journey. If you actually start with the very first insulin, there are about 30,000 kids diagnosed a year in the U.S. This is an opportunity to really transform that long-term, TAM, I'll say, as you think about the insulin-dependent market. About 50% of all insulin use in the U.S. is specifically related to type 1 diabetes. While GLPs are impacting the type 2 market, the insulin market overall is relatively flat. The real influence of insulin utilization starts with kids and goes to adults and is related to the type 1 market. Over the next 15-20 years, that's how we see this market evolving. If we could become that first insulin choice, you can start to see that compound growth happen over the next 5 and 10 years pretty quickly. We're kicking off this trial. It'll be in conjunction with the JDRF and 10 of the top centers in the U.S. We'll do the first 10 patients, make sure the dosing's right and it's tight 'cause this is a newly diagnosed setting. They still have some residual beta cell function. You are really trying to measure how they are doing as they get back from, call it a 9, 10 A1C down to a 7, in the first 13 weeks. We will be watching that closely, and then we will continue on for an additional 26 weeks. We say up to 100 patients because we do expect FDA approval. Once it is approved, patients may or may not want to go into trial. We will be able to stop it short if we need to, but otherwise we will try to get this done in 2026. We are introducing two things in this trial. One is a two-unit cartridge. We do not think clinically it is needed, but I think when you look at our previous data, what we heard from caregivers and doctors was we were afraid to titrate up. Does by offering a two-unit increment allow people to titrate up a little bit? That'll be the first time we really test that cartridge in clinical patients. You got BluHale Device, which is a, we've updated this to now have a new app with CGM and Dexcom where you really overlay the CGM data along with the dosing of the cartridge and really showing that real-time insulin control on a daily basis. We'll be looking at timing range and starting to use, collect that data 'cause eventually AI and insulin are gonna be hand in hand as we think about a disease that really could use AI predictions. The second big area that kind of came out over last year when people saw our data was GDM. This was unsolicited, by physicians who were in our trial saying with this type of postprandial control, and just so you know the data that's coming out, we're seeing about a 35%-45% reduction in the post 2 hours of eating and postprandial control with AFREZZA over standard of care. If you really think about eating 3-5 times a day, snacks, and you can reduce your postprandial excursion by 30%-40%, that all of a sudden becomes meaningful data. That's a lot of the new data we generated. When they saw that, they said, you gotta really look at this for gestational diabetes. I'll remind you, it's human insulin, it's water and FDKP. We like those ingredients. They're safe. They felt if this is safe in GDM, why the only things available on the guidelines is metformin, which they do not like, and injectable insulin. A pregnant woman who has to use insulin for 8- 12 weeks would much rather take an inhaled product for a short period of time and be done. About 10%-20% of those patients will wind up with diabetes at some point. It is also an opportunity to raise awareness as an option for patients. The first 10 patients were done. We looked at a safety analysis for them. The data looked good, so we proceeded to the next 20. This should wrap up over the next few months here. So far we are looking like we are standing up pretty well in this goal of less than 120 over three hours. When we think about the value drivers, from a revenue perspective, our pro forma revenues post SC, you can see we broke $100 million in Q3. When you look at both of these combined, you can see the royalties from United Therapeutics to collaboration and the endocrine. We also have a small product called Vigo, which we stopped marketing a little over a year ago. Continued growth year-over-year. We do not see anything really slowing us down, in terms of the products. We will continue to add FUROSCIX, in Q4 as the deal closed. We look forward. When you look at building value, obviously Tyvaso DPI is a core foundation for the company in the short term. Then you look at the cardiometabolic with AFREZZA growing in peds this year, FUROSCIX, you know, there is, there is, a couple million patients. When you think about every 100,000 patients is about $350 million in revenue. Large opportunity and large unmet need. We know there's competition coming, but we think the market can sustain multiple competitors launching in this area where, you know, just raising awareness of how to use these products at home and get people outta the hospital is a huge opportunity that is just a new paradigm shift. We continue to see that market building and we'll be differentiated, company in that place over the coming years. Nintedanib DPI, obviously Ofev's a large molecule. We see this continue to be part of the backbone of treatment. It'll do over $4 billion this past year. Advance of bumetanide, this is a PK/PD manufacturing is probably a long lead time here. Very fast product to market, when we look at out as opportunities. Then you got the second collaboration here with United Therapeutics. We look at our pipeline opportunities here. We're well diversified with inline revenue, diversified on the pipeline, and we really look forward to working with investors and patients and providers over the coming years. I'll stop there and take any questions.